SA
RDY icon

Shilanski & Associates’s Dr. Reddy's Laboratories RDY Stock Holding History

Shilanski & Associates’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,690
Closed -$224K – 112
2020
Q4 		$224K Sell
15,690
-420
-3% -$5.66K 0.14% 88
2020
Q3 		$224K Buy
+16,110
New +$192K 0.15% 82

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Shilanski & Associates's RDY Position: Q1 2021 in Review

Shilanski & Associates sold out of Dr. Reddy's Laboratories (RDY) in Q1 2021, closing a stake of 15,690 shares — an estimated $224K sold.

Shilanski & Associates first reported a position in RDY in Q3 2020 and held it in 2 quarters. The position peaked at $224K in Q4 2020. 160 funds tracked by Wall St. Rank hold RDY as of Q1 2021.

  • Shilanski & Associates reported no remaining Dr. Reddy's Laboratories position as of Q1 2021 after selling out during the quarter.
  • Shilanski & Associates sold 15,690 Dr. Reddy's Laboratories shares in Q1 2021, an estimated $224K.
  • Shilanski & Associates first reported a position in Dr. Reddy's Laboratories in Q3 2020 and held it in 2 quarters.
  • Shilanski & Associates's Dr. Reddy's Laboratories position peaked at $224K in Q4 2020.
  • 160 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2021.

Based on Shilanski & Associates's 13F filing for Q1 2021, filed 14 Apr 2021.